Overview
Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement
Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year
Palatin completes $18.2 mln public offering, regains NYSE American compliance
Outlook
Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026
Palatin expects mid-2026 IND filing for next-gen MC4R agonists
Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity
Result Drivers
BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement
PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 EPS | $4.26 |
Press Release: ID:nPnf1Qmja
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)